ALK to start phase I trial of peanut allergy tablet vaccine
In 2021, ALK announced that it was preparing for clinical trials of a peanut allergy treatment, and it has now relayed that the firm will soon start recruitment for an upcoming study.
by marketwire, translated by catherine brett
ALK is starting its clinical trial of a tablet vaccine against peanut allergies, it reveals in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK CEO sells shares for USD 1.5m
For subscribers
